Stockreport

Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation? [Yahoo! Finance]

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF Denali Therapeutics is estimated to be 50% undervalued based on current share price of US$15.43 Analyst price target for DNLI is US$40.27, which is 31% above our fair [Read more]